KZIA KZIA
Company Profile ↓Company Overview
KZIA (KZIA) is a publicly traded company listed on with a market capitalization of $9.71B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Recent Developments
- Jun 2025 Revenue of $42.00K (-98.2% YoY); net profit $-20.70M.
- Trailing 12 Months Year-on-year growth — revenue -98.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -98.18% |
Stock Price Performance
| 1 Year: | +38.41% |
| 6 Months: | +98.02% |
| 3 Months: | -10.78% |
| 1 Month: | -8.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)41.55 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 2.31M | 42.00K |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 25.40M | 24.15M | 30.77M | 14.26M |
| Operating Income | -25.40M | -24.15M | -28.46M | -14.22M |
| EBITDA | -23.53M | -22.28M | -26.59M | -13.28M |
| Interest Expense | - | - | - | - |
| Pretax Income | -25.38M | -20.74M | -27.05M | -22.45M |
| Tax Provision | -368.00K | -271.00K | -271.00K | -1.75M |
| Net Income | -25.01M | -20.46M | -26.78M | -20.70M |
| Diluted EPS | -93.05 | -56.15 | -50.80 | -18.90 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 35.89M | 28.08M | 21.59M | 6.06M |
| Current Assets | 9.45M | 10.77M | 6.14M | 4.93M |
| Cash & Equivalents | 7.36M | 5.24M | 1.66M | 4.34M |
| Inventory | - | - | - | - |
| Receivables | 0 | 1.00K | 0 | - |
| Total Liabilities | 17.61M | 16.03M | 31.60M | 14.36M |
| Current Liabilities | 6.73M | 7.57M | 25.80M | 14.05M |
| Long Term Debt | - | - | - | - |
| Total Debt | 1.84M | 1.80M | 634.00K | 396.00K |
| Total Equity | 18.27M | 12.05M | -10.02M | -8.30M |
| Shares Outstanding | 138.76M | 228.03M | 332.85M | 809.42M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -22.76M | -15.16M | -9.58M | -13.28M |
| Investing Cash Flow | -2.37M | 0 | 0 | - |
| Financing Cash Flow | 3.73M | 12.97M | 5.99M | 15.98M |
| Capital Expenditure | - | - | - | - |
| Free Cash Flow | -22.76M | -15.16M | -9.58M | -13.28M |
| Net Change in Cash | -21.40M | -2.18M | -3.60M | 2.70M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | -1,233.2% | -33,850.0% |
| Net Margin % | - | - | -1,160.2% | -49,290.5% |
| ROE % | -136.9% | -169.8% | 267.3% | 249.4% |
| ROCE % | -87.1% | -117.7% | 675.7% | 177.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KZIA
Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
Clinically relevant perioperative studies demonstrate elimination of residual disease and prevention of metastatic spread, supported by complementary translational patient dataSYDNEY, July 28, 2026 (GLOBE NEWSWIRE) -- Kazia Therapeutics Lim…
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the ap…
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced plans to expand its ongoing …
How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform
Kazia Therapeutics Ltd (NASDAQ:KZIA) is among the best Australian stocks to buy in 2026. Kazia Therapeutics Ltd (NASDAQ:KZIA) recently strengthened its team and expanded its platform as it works to address unmet needs in the cancer treatmen…
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the appointment of Dr. Sudha Rao as Chief Scientific Officer (CSO).…
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class SETDB1-targeted epigenetic drug d…
KZIA — Frequently Asked Questions
What is the current share price of KZIA?
As of 2026-08-05 17:25 PDT, KZIA trades at $12.00 on NASDAQ/NYSE. Its 52-week range is $5.00 to $15.72.
What is the market capitalisation of KZIA?
KZIA has a market capitalisation of $9.71B on NASDAQ/NYSE.
What is the P/E ratio of KZIA?
KZIA trades at a trailing price-to-earnings (P/E) ratio of -0.63.
Is KZIA a good stock to buy?
This page provides a data-driven analysis of KZIA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.